The U.S. Biosimilar Market: Do Analysts Have It Wrong?
White Paper|
By Barrett Rankin, Partner; Gautam Aggarwal, Partner; Alex Sherman, Strategy Consultant; Rachel Clare, Strategy Consultant
In this paper, Triangle Insights proposes a framework to more accurately predict biosimilar penetration by accounting for key factors influencing physicians, patients, and payers.
The U.S. Biosimilar Market: Do Analysts Have It Wrong?
Please submit the form below to view this resource.
Request Access
Please fill out the form below to access our Industry Resources.
By submitting this form, you agree to our use of this information for the purpose of contacting you. For more information, please refer to our privacy policy.